Wednesday, October 28, 2009
You DO NOT need an appointment for any of our locations. The administration fee is $15.00, we accept cash or check.
Below are the following counties and the type of vaccine we have received. You can visit www.GetMyFluShot.com to find the dates and addresses of each location.
Hewitt, NJ-Passaic County- Nasal spray for those healthy people aged 2-49 yrs, and injectable vaccine for those aged 3 years to 64 years.
Manahawkin, NJ- Ocean County- Nasal spray for those healthy people aged 2-49 yrs, and injectable vaccine for those aged 3 years to 64 years.
Toms River, NJ- Ocean County- Nasal spray for those healthy people aged 2-49 yrs, and injectable vaccine for those aged 3 years to 64 years.
Point Pleasant, NJ- Ocean County- Nasal spray for those healthy people aged 2-49 yrs, and injectable vaccine for those aged 3 years to 64 years.
Ocean City, NJ- Cape May County- Nasal spray for those healthy people aged 2-49 yrs, and injectable vaccine for those aged 3 years to 64 years.
North Bergen and Bayonne, NJ - Hudson County- Nasal spray for those healthy people aged 2-49 yrs, and injectable vaccine for those aged 3 years to 64 years.
Holmdel and Englishtown, NJ - Monmouth County- Nasal spray ONLY for those healthy people aged 2-49 yrs
Sussex and Vernon, NJ- Sussex County- Nasal spray for those healthy people aged 2-49 yrs, and injectable vaccine for those aged 3 years to 64 year.
When vaccine is first available, the CDC Advisory Committee on Immunization Practices (ACIP) has recommended the 2009 H1N1 vaccine for the following 5 target groups (approximately 159 million persons nationally):
- Pregnant women
- Household and caregiver contacts of children younger than 6 months of age (e.g. parents, siblings, and daycare providers)
- Health care and emergency medical services personnel
- Persons from 6 months through 24 years of age
- Persons aged 25 through 64 years who have medical conditions associated with a higher risk of influenza complications
Tuesday, September 1, 2009
Point Pleasant Beach plans cat roundup after rabies outbreak
by The Star-Ledger Continuous News Desk Saturday August 29, 2009, 12:41 PM
Point Pleasant Beach plans to round up feral cats after an outbreak of rabies in a town home to an estimated 300 stray cats, a report in the Asbury Park Press said.
Attacks by cats, including two children in separate incidents, alarmed residents, who expressed concerns in a Wednesday town hall meeting, according to the report. A cat that tested positive for rabies attacked 17-year-old Kenny Pringle in his backyard, the report said.
Officials said they plan to capture stray cats and place them in cages in rented, climate-controlled trailers for 60 days of observation, according to the report. Authorities will kill infected cats, while healthy adult cats will be vaccinated, neutered and returned to their colonies, the report said. Kittens will be put up for adoption.
Council members said the stray cat problem stems from people abandoning pets, and others providing food and water to colonies.
ESI Medical provides pre and post exposure rabies vaccinations at significantly lower pricing than most medical facilities.
Tuesday, August 4, 2009
Novel H1N1 vaccine is being procured by the U.S. government from five (5) vaccine manufacturers of currently U.S.-licensed seasonal influenza vaccines – inactivated subunit (4) and live, attenuated vaccines (1). Inactivated licensed novel H1N1 vaccine will be available in single-dose syringes, or in multi-dose vials. Live attenuated vaccine will be available in limited number in inhaler sprayers. Single-dose syringes will be thimerosal-free, which will address concerns about this additive, especially regarding pediatric and pregnant vaccine recipients (inhaler sprayer vaccine products will also be thimerosal-free). The availability of novel H1N1 vaccine is dependent on multiple factors including virus growth at commercial scale, regulatory review, availability of calibrated vaccine product potency assay reagents, overall production capacity, and availability to U.S. through HHS contracts.
Vaccine purchase and allocation
Novel H1N1 vaccine is being purchased by the U.S. government and will be made available for vaccinators at no cost. Syringes, needles, sharps containers and alcohol swabs will also be provided. Vaccine will be allocated across states proportional to population. State health departments (and a few separately funded cities) will direct their allocation to local health departments and other vaccination partners.
Go to www.getmyflushot.com or www.ANeedleFreeFluVaccine.com for more information
Monday, March 30, 2009
This vaccine has been licensed by the FDA and approved by CDC as safe and effective. It was studied in thousands of females (ages 9 through 26 years) around the world and its safety continues to be monitored by CDC and the FDA. Studies have found no serious side effects. The most common side effect is soreness in the arm (where the shot is given). There have recently been some reports of fainting in teens after they got the vaccine. For this reason, it is recommended that patients wait in their doctor’s office for 15 minutes after getting the vaccine.
What about vaccinating boys and men?
We do not yet know if the vaccine is effective in boys or men. It is possible that vaccinating males will have health benefits for them by preventing genital warts and rare cancers, such as penile and anal cancer. It is also possible that vaccinating boys/men will have indirect health benefits for girls/women. Studies are now being done to find out if the vaccine works to prevent HPV infection and disease in males. When more information is available, this vaccine may be licensed and recommended for boys/men as well.
Thursday, February 12, 2009
Key point: The CDC Advisory Committee on Immunization Practices (ACIP) recommends that cigarette smoking be added to the list of indications for use of 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults 19 to 64 years of age.
Finer points: In October, ACIP voted on new recommendations for use of the pneumococcal vaccine for prevention of invasive pneumococcal disease. A key recommendation was the addition of cigarette smoking as an indication for the vaccine in adult patients. The proposed wording of the revised recommendation was "Persons aged 19 through 64 years who smoke cigarettes should receive a single dose of PPSV23 and smoking cessation counseling." This recommendation was based on a multitude of data showing that patients who smoke are at substantially increased risk for invasive pneumococcal disease. Nuorti and colleagues conducted a population-based case-control study to assess risk factors for pneumococcal disease. The investigators reported that cigarette smoking was the strongest independent risk factor (odds ratio 4.1 [95% CI 2.4–7.3]) for invasive pneumococcal disease among immunocompetent adults 18 to 64 years old. Passive smoking among nonsmokers was the second strongest risk factor (2.5 [1.2–5.1]) for the disease. The investigators also noted dose–response relationships for the current number of cigarettes smoked per day, pack–years of smoking, and time since quitting. Pastor and colleagues reported similar findings, with smoking being a risk factor for pneumococcal disease among young and middle-aged patients. The 2007 Infectious Diseases Society of America and American Thoracic Society guidelines for the management of community-acquired pneumonia (CAP) in adults also recommended that smoking cessation be a goal for patients hospitalized with CAP who smoke and that smokers who do not quit be vaccinated with both the pneumococcal and influenza vaccines.
What you need to know: Approximately 20% of U.S. adults are estimated to smoke cigarettes. Smoking is thought to cause structural changes in the respiratory tract and a decrease in immune response, which makes smokers more susceptible to developing bacterial and viral infections. ACIP’s recommendation for vaccinating adult patients who smoke is currently under review by CDC and the Department of Health and Human Services and will become official when published in CDC's Morbidity and Mortality Weekly Report. If approved, the new ACIP recommendation will significantly increase the number of adult patients who qualify for the pneumococcal vaccine. This offers an opportunity for pharmacists to become actively involved in identifying patients who smoke, vaccinating them against pneumococcal disease, and counseling them on smoking cessation options and the harmful effects of secondhand smoke. Community-based vaccination programs can easily identify patients at greatest risk for pneumococcal disease and improve overall vaccination rates.
What your patients need to know: Adult patients who currently smoke should be told that they are at an increased risk for invasive pneumococcal disease. Educate patients about the benefits of receiving the pneumococcal vaccine and counsel them on the importance of smoking cessation and avoiding secondhand smoke.